MEHMETCAN ATAK

Dr. MEHMETCAN ATAK

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
MEMert Eşme
Mert Eşme
OBOktay Bulur
Oktay Bulur
MAMEHMETCAN ATAK
MEHMETCAN ATAK
CBCafer Balci
Cafer Balci
KDKürşat Dal
Kürşat Dal
BDBurcu Balam Dogu
Burcu Balam Dogu
Renal function of patients with hypothyroidism increases after reaching euthyroid state.There is no data regarding geriatric age group. Investigate whether renal function of geriatric patients with hypothyroidism increases after they become euthyroid. 65 years or older were retrospectively screened in two centers.TSH, T3, T4, creatinine and eGFR calculated by CKD-EPI formula were recorded under the presence of accompanying hypothyroidism.The same variables were recorded after the patients became euthyroid. 285 patients were included in the study.The median age was 73(65-84). 234 patients were female.Patients were examined in four groups according to TSH values.There were 160 (56.1%) patients with TSH 5-9.9 uIU/mL, 60(21.1%) patients with TSH between 10-19.9 uIU /mL, 41(14.4 %) patients with TSH between 20-49.9 uIU/mL and 24(8.4%) patients with TSH> 50uIU/mL.There was a significant and negative correlation between the initial TSH values and the first calculated eGFR values(p:0.001; r:-0.191).The median eGFR of the patients in hypothyroid cases was 66.59 (14.62-116.07), while the median eGFR value of patients was 69.6 (12.91-109.31)in the euthyroid state.This value obtained after thyroid replacement was significantly improved when compared to the first eGFR(p:0.001).In logistic regression analysis, pretreatment TSH value was found to independently affect eGFR (p:0.009;Exb: 1.017). It has been observed that hypothyroidism treatment increases eGFR in geriatric patients.Similar results were obtained after studies with younger patients in the literature.. This study is a study in which only geriatric age group patients were examined.It should be kept in mind that hypothyroidism which is not corrected in geriatric patients may also contribute to a decrease in eGFR.

24 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SÇselahattin çelik
selahattin çelik
EKEngin Eren Kavak
Engin Eren Kavak
EZEsra Zeynelgil
Esra Zeynelgil
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
IDİsmail Dilli
İsmail Dilli
TETülay Eren
Tülay Eren
Background: Immune checkpoint inhibitors (ICIs) targeting the PD-1 axis represent standard second-line therapy for metastatic non-small cell lung cancer (NSCLC). Emerging data suggest that SARS-CoV-2 mRNA vaccines may enhance antitumor immunity through innate immune activation and type I interferon signaling, potentially sensitizing tumors to PD-1 blockade. The clinical impact of patients initiating second-line nivolumab remains unclear. Methods: In this retrospective single-center cohort study, 88 patients with recurrent stage IV NSCLC who received second-line nivolumab between 1 January 2023 and 1 January 2026 were analyzed. Vaccination exposure was defined using a 6-month pre-treatment window prior to nivolumab initiation (T0). Patients were stratified according to receipt of ≥2 versus 0–1 mRNA COVID-19 vaccine doses within the 6 months preceding T0 (n = 45 and n = 43, respectively). The primary endpoint was progression-free survival from nivolumab initiation (PFS2). Survival outcomes were estimated using the Kaplan–Meier method and evaluated using Cox regression models. Results: With a median follow-up of 22.4 months, median PFS2 for the overall cohort was 11.1 months (95% CI, 9.4–15.1). Patients receiving ≥2 mRNA doses had significantly longer PFS2 than those receiving 0–1 dose (14.0 vs. 9.6 months; p = 0.04). In multivariable analysis, ≥2 doses were independently associated with reduced risk of progression or death (aHR 0.52, 95% CI 0.31–0.88; p = 0.01). Non-adenocarcinoma histology and baseline brain metastasis were independently associated with shorter PFS2. Conclusions: Receipt of ≥2 mRNA vaccine doses within 6 months before nivolumab initiation was independently associated with prolonged PFS2 in metastatic NSCLC. Prospective multicenter validation is warranted.

7 March 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
SSSerhat Sekmek
Serhat Sekmek
IKIRFAN KARAHAN
IRFAN KARAHAN
GUGokhan Ucar
Gokhan Ucar
FCFurkan Ceylan
Furkan Ceylan
DBDogan Bayram
Dogan Bayram
DUDoğan Uncu
Doğan Uncu

17 June 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SÇselahattin çelik
selahattin çelik
SKSalih Karatlı
Salih Karatlı
MAMEHMETCAN ATAK
MEHMETCAN ATAK
HSHatice Ayyıldız Sevim
Hatice Ayyıldız Sevim
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
SRSamed Rahatlı
Samed Rahatlı
Background and Objectives: Quality of life (QoL) has become an essential outcome in patients with metastatic prostate cancer, particularly in the era of androgen receptor (AR)-targeted therapies. Although these agents improve survival, their differential impact on QoL and the role of psychological factors remain incompletely understood. This study aimed to evaluate QoL, functional outcomes, and psychological status, and to identify factors associated with poor QoL in a real-world cohort. Materials and Methods: This prospective cross-sectional, single-center observational study included 130 patients with metastatic prostate cancer receiving AR-targeted therapies (abiraterone, enzalutamide, or apalutamide/darolutamide). QoL was assessed using the EORTC QLQ-C30 questionnaire, and psychological status was evaluated using the Hospital Anxiety and Depression Scale (HADS). Patients were stratified according to treatment groups, and comparisons were performed using appropriate statistical tests. Logistic regression analyses were conducted to determine factors independently associated with poor QoL. Results: Exploratory differences in global QoL were observed among treatment groups (p = 0.007), with lower global QoL scores in the abiraterone group and numerically higher emotional and cognitive functioning scores in the enzalutamide group. Symptom analysis demonstrated higher nausea/vomiting scores in the abiraterone group (p = 0.022), whereas other symptom domains were comparable across treatment groups. In multivariable analysis, anxiety (odds ratio [OR]: 6.62) and depression (OR: 3.40) were independently associated with poor QoL, while treatment type was not independently associated with poor QoL after multivariable adjustment. Conclusions: Although unadjusted QoL scores differed across AR-targeted therapy groups, psychological factors—particularly anxiety and depression—were significantly associated with poorer QoL in patients with metastatic prostate cancer. These findings highlight the importance of integrating routine psychosocial assessment and supportive care strategies into clinical practice to optimize patient-centered outcomes. However, given the cross-sectional and exploratory nature of the study, the findings should be interpreted cautiously.

26 August 2026 in Radiation Sciences in Oncology
Verified
Journal Article
Open access
PDF file
GKGizem Kavak
Gizem Kavak
MAMEHMETCAN ATAK
MEHMETCAN ATAK
OSOsman Sutcuoglu
Osman Sutcuoglu
SŞSemra Demirtaş Şenlik
Semra Demirtaş Şenlik
ÖÖÖzlem Özmen
Özlem Özmen
YGYıldız Güney
Yıldız Güney
Objective: Total neoadjuvant therapy (TNT) is increasingly used for locally advanced rectal cancer, but factors associated with metabolic tumor response remain unclear. This study aimed to explore correlations between fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT)-derived metabolic tumor response and patient-related factors, including body composition, systemic inflammatory markers, and imaging-based biomarkers, in patients receiving TNT. Materials and Methods: This retrospective single-center study included 15 patients with locally advanced rectal cancer who underwent baseline and post-treatment FDG PET/CT imaging. Metabolic tumor parameters, including maximum standardized uptake value (SUVmax), standardized uptake value normalized to lean body mass mean (SULmean), total lesion glycolysis (TLG), and metabolic tumor volume (MTV), were extracted, and percentage changes were calculated. Psoas muscle area, psoas muscle index (PMI), and subcutaneous fat were measured from the CT component, while spleen-to-liver ratio (SLR), liver-to-rectus femoris ratio (LRF), and laboratory inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), albumin, and C-reactive protein (CRP), were assessed as host-related variables. Results: Significant reductions were observed in all metabolic PET/CT parameters after treatment. Psoas muscle area and PMI showed significant negative correlations with percentage changes in all four metabolic parameters, with correlation coefficients ranging from −0.614 to −0.879, suggesting that higher psoas-derived muscle measurements may be associated with greater metabolic reduction after treatment. Albumin change was significantly correlated with TLG and MTV response. In contrast, NLR, PLR, CRP, and subcutaneous fat showed no significant associations with metabolic tumor response. The SLR correlated modestly with MTV change only. Conclusion: Baseline psoas-derived muscle measurements, particularly PMI, may be associated with metabolic tumor response after TNT in locally advanced rectal cancer. These findings should be considered preliminary and hypothesis-generating and may support further evaluation of body composition assessment during pre-treatment evaluation of this patient population.

Verified
Journal Article
Open access
PDF file
SSSerhat Sekmek
Serhat Sekmek
AOAYSEL OĞUZ
AYSEL OĞUZ
MEMelek Karakurt Eryılmaz
Melek Karakurt Eryılmaz
MAMurat Araz
Murat Araz
SBSedat Biter
Sedat Biter
GUGokhan Ucar
Gokhan Ucar
Background/Objectives: In this retrospective study, we aimed to compare the efficacy, survival, and toxicity results of induction (IC) or adjuvant (AC) treatment with chemoradiotherapy (CRT) in locally advanced nasopharyngeal cancer (NPC). Methods: A total of 405 patients from 22 different centres in Turkey, belonging to the Turkish Oncology Group (TOG), was included. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoints were safety and toxicity. Results: The median age of the patients included in the study was 49 (18.2–91.5) years. In total, 298 (73.6%) of the patients were male. Of the 405 patients, 258 (63.7%) received IC and 147 (36.3%) received AC treatment. When OS and PFS analyses were performed in terms of age, gender, T and N stages, pathological features, and treatments received, no effect of any variable on prognosis was observed. For the overall group, the median estimated OS was 137.3 months (the Kaplan–Meier statistical method could not reach the 95% confidence interval [CI]). For the IC group, the median estimated survival was 137.3 months (95% CI: 111.4–163.3), whereas the Kaplan–Meier statistical method could not estimate survival for the AC group. No statistically significant difference was observed between IC and AC groups in terms of OS (p = 0.209) or PFS (p = 0.248). Grade 3–4 side effects were observed in 12% of patients in the IC group and 29.9% of patients in the AC group. Treatment was discontinued due to toxicity in 5 patients (1.9%) in the IC group and 18 patients (12.2%) in the AC group. Conclusion: No difference in OS or PFS was observed between AC and IC treatments. More grade 3–4 side effects were observed in the AC-treated group and early discontinuation rate was higher.